Pasithea Therapeutics (KTTA) Cash & Equivalents (2020 - 2026)

Pasithea Therapeutics has reported Cash & Equivalents for 7 years, with the latest figure at $50.4 million in Q1 2026.

• Quarterly Cash & Equivalents rose 843.59% year-over-year to $50.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.4 million (up 843.59% YoY) and the FY2025 annual result came in at $55.2 million, up 697.37% from the prior year.
• Cash & Equivalents slipped to $50.4 million in Q1 2026 per KTTA's latest filing, from $55.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $55.2 million in Q4 2025 and troughed at $4.1 million in Q3 2025.
• A 5-year average of $24.9 million and a median of $19.6 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2026: Cash & Equivalents slumped 73.36% in 2024, then surged 843.59% in 2026.
• Over 5 years, Cash & Equivalents stood at $33.1 million in 2022, then sank by 50.64% to $16.3 million in 2023, then plunged by 57.61% to $6.9 million in 2024, then surged by 697.37% to $55.2 million in 2025, then fell by 8.7% to $50.4 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $50.4 million, $55.2 million, and $4.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.